Welcome to Vimpat. This site is screen reader friendly.

Skip to content Skip to main navigation Skip to footer navigation

Vimpat is a first-in-class antiepileptic drug (AED) that offers power for the adjunctive treatment for partial-onset seizures. It has shown effectiveness with the broadest range of AEDs, including second- and first-generation agents.¹

Efficacy Proven With the Broadest Range of AEDs

Drug List: Levetiracetam, Oxcarbazepine, Phenytoin, Topiramate, Divalproex Sodium, Carbamazepine, Lamotrigine, Phenobarbital, Zonisamide

In clinical trials, many patients taking Vimpat had their seizures reduced by half or more at rates that were significantly greater than placebo groups. Results from an open label clinical trial show a high long-term retention rate.

This section provides a more detailed view of these results, demonstrating the efficacy and long-term tolerability of Vimpat.

Indication

Vimpat^® (lacosamide) tablets and oral solution are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat injection is indicated as short-term replacement when oral administration is not feasible in these patients.

Important Safety Information

Warnings and Precautions

AEDs increase the risk of suicidal behavior and ideation. Patients taking Vimpat should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Patients should be advised that Vimpat may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In patients with seizure disorders, Vimpat should be gradually withdrawn to minimize the potential of increased seizure frequency. Multiorgan hypersensitivity reactions have been reported with antiepileptic drugs. If this reaction is suspected, treatment with Vimpat should be discontinued.

Vimpat oral solution contains aspartame, a source of phenylalanine. A 200-mg dose of Vimpat oral solution (equivalent to 20 mL) contains 0.32 mg of phenylalanine.

Common Adverse Reactions

The most common adverse reactions occurring in ≥10 percent of Vimpat-treated patients, and greater than placebo, were dizziness, headache, nausea, and diplopia.

Dosage adjustments are recommended for patients with mild or moderate hepatic impairment or severe renal impairment. Use in severe hepatic impairment patients is not recommended.

Please see Vimpat Prescribing Information.